Last reviewed · How we verify
delta-24-RGD adenovirus — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
delta-24-RGD adenovirus (delta-24-RGD adenovirus) — Erasmus Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| delta-24-RGD adenovirus TARGET | delta-24-RGD adenovirus | Erasmus Medical Center | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- delta-24-RGD adenovirus CI watch — RSS
- delta-24-RGD adenovirus CI watch — Atom
- delta-24-RGD adenovirus CI watch — JSON
- delta-24-RGD adenovirus alone — RSS
Cite this brief
Drug Landscape (2026). delta-24-RGD adenovirus — Competitive Intelligence Brief. https://druglandscape.com/ci/delta-24-rgd-adenovirus. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab